Attention-Deficit/Hyperactivity Disorder | Disease Landscape and Forecast | G7 | 2018

Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both pediatric and adult ADHD include controlling the core symptoms of the condition—inattention and/or hyperactivity/impulsivity—as well as improving patients’ overall functioning and quality of life. Psychostimulants are the predominant drug class prescribed for both pediatric and adult ADHD, though nonstimulant therapies serve as alternative or later-line options. Shortcomings in existing therapies, however, represent potential areas of opportunity for emerging therapies to be differentiated from competitors. Furthermore, recognition and diagnosis of adult ADHD continues to grow, particularly in the United States, but this population remains underdetected and undertreated, representing a sizable market opportunity.

Questions Answered

  • What is the current state of treatment for pediatric and adult ADHD across the G7, and what needs are left unfulfilled by current ADHD therapies?
  • How has the entrance of generic competition to key drugs (e.g., Eli Lilly’s Strattera [atomoxetine]) modified the ADHD treatment landscape?
  • How have newer-to-market and brand-only agents (e.g., Shire’s Mydayis, Neos Therapeutics’ Adzenys ER) been incorporated into medical practice? What are physicians’ perception of these therapies?
  • What emerging therapies do ADHD thought leaders consider the most promising for pediatric ADHD and adult ADHD?

Product description: Disease Landscape & Forecast provides comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 16 country-specific interviews with thought-leading psychiatrists and pediatricians, supported by survey data.

Epidemiology: Prevalence of ADHD by country, segmented by pediatric and adult ADHD.

Emerging therapies: Phase II: 6 drugs; Phase III: 6 drugs; preregistration/registration: 2 drugs. Coverage of select preclinical and Phase I products.

Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ADHD therapies through 2027, segmented by brands/generics and pediatric/adult ADHD.

Key companies: Shire, Janssen, Novartis, Eli Lilly, Arbor Pharmaceuticals, Neos Pharmaceuticals, Pfizer, Ironshore Pharmaceuticals, Supernus Pharmaceuticals, Sunovion.

Key drugs: Vyvanse, Concerta, Strattera, Adderall, Ritalin, Mydayis, Focalin, Dexedrine, Intuniv.

Login to access report

launch Related Market Assessment Reports